Andrx' President Elliot Hahn and CFO Angelo Malahias talk to The Wall Street Transcript.

Business Editors

NEW YORK--(BUSINESS WIRE)--Oct. 16, 2000

The Wall Street Transcript has published an in-depth interview with Elliot Hahn, President, and Angelo Malahias, CFO, both at Andrx Corporation (Nasdaq:ADRX), in which they talk at length about the company's future.

The entire 3,000-word interview is available free online at http://www.twst.com/ceos.htm

Hahn gives an overview of the company. "Our initial strategy was to develop difficult-to-replicate controlled-release oral pharmaceutical products, and we focused on making generic or bioequivalent versions of these products. Currently we have filed 11 ANDAs with the FDA, of which two are already on the market; Dilacor XR and Cardizem CD generics, which we've trademarked and sell under the names Diltia XT and Cartia XT. We have nine ANDAs pending at the FDA that address approximately $6 billion in current brand sales."

Malahias explains, "Our distribution business, which was started in late 1992, has had 32 consecutive quarters of increase in sales or gross profits. And there is an extremely large dollar value of products that could be genericized over the next couple of years that could fuel the continued growth of our distribution operation."

Looking forward, Hahn states, "Now with the technology base that we have built up, we believe that the next level will be for Andrx to move on to the brand side. However, we will not abandon our generic program, but complement it by this additional strategy. We think we can address a brand program more

aggressively by utilizing some of the funds that Andrx recently raised in an offering held in May. We have approximately $325 million or so of cash with no long-term debt."

This interview is part of a 166-page Specialty Pharmaceuticals, Generics & Drug Delivery Companies Issue available at http://www.twst.com/info/info190.htm or by calling [phone].

The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 37 years.

The Wall Street Transcript has launched a new free service where investors can ask Andrx Corporation (or any public company) a question at http://www.qawire.com.

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call [phone].